Exogenous administration of visfatin affects cytokine secretion and increases oxidative stress in human malignant melanoma Me45 cells

Journal of Physiology and Pharmacology

Volumn 64, Issue 3, 2013, Pages

  Buldak, Rafal Jakub ^a   Polaniak, R ^a   Buldak, L ^a   Mielanczyk, L ^a   Kukla, M ^a   Skonieczna, M ^b   Dulawa Buldak, A ^a   Matysiak, N ^a   Zwirska Korczala, K ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b SILESIAN UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

Activation; Cytokines secretion; Melanoma; Nuclear factor kappa B; Reactive oxygen species; Visfatin

Indexed keywords

DICHLORODIHYDROFLUORESCEIN DIACETATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR RELA; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; ANTINEOPLASTIC AGENT; CHROMONE DERIVATIVE; COUMARIN DERIVATIVE; CYTOKINE; ENZYME INHIBITOR; MORPHOLINE DERIVATIVE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE, HUMAN; PROTEIN KINASE INHIBITOR; RECOMBINANT PROTEIN; RELA PROTEIN, HUMAN; TUMOR PROTEIN; WEDELOLACTONE;

ADULT; ARTICLE; BIOASSAY; CANCER CELL CULTURE; CASE REPORT; CELL STIMULATION; CHEMOLUMINESCENCE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRACELLULAR SIGNALING; MELANOMA CELL; MOLECULAR DYNAMICS; OXIDATIVE STRESS; SUPERNATANT; AGONISTS; ANTAGONISTS AND INHIBITORS; CELL LINE; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECTS; GENETICS; IMMUNOLOGY; MELANOMA; METABOLISM; SECRETION (PROCESS); SIGNAL TRANSDUCTION; TUMOR CELL LINE; UPREGULATION;

ANTINEOPLASTIC AGENTS; CELL LINE; CELL LINE, TUMOR; CHROMONES; COUMARINS; CYTOKINES; ENZYME INHIBITORS; HUMANS; MELANOMA; MORPHOLINES; NEOPLASM PROTEINS; NF-KAPPA B; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OXIDATIVE STRESS; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN KINASE INHIBITORS; REACTIVE OXYGEN SPECIES; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR RELA; UP-REGULATION;

EID: 84895911899     PISSN: 08675910     EISSN: 18991505     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Fernandez-Sanchez A, Madrigal-Santillan E, Bautista M, et al. Inflammation, oxidative stress, and obesity. Int J Mol Sci 2011; 12: 3117-3132.
2. Dalamaga M, Archondakis S, Sotiropoulos G, et al. Could serum visfatin be a potential biomarker for postmenopausal breast cancer? Maturitas 2012; 71: 301-308.
3. Nakajima TE, Yamada Y, Hamano T, et al. Adipocytokines as new promising markers of colorectal tumors: adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer. Cancer Sci 2010; 101: 1286-1291.
4. Nakajima TE, Yamada Y, HamanoT, et al. Adipocytokine levels in gastric cancer patients: resistin and visfatin as biomarkers of gastric cancer. J Gastroenterol 2009; 44: 685-690.
5. Catalan V, Gomez-Ambrosi J, Rodriguez A, et al. Association of increased visfatin/PBEF/NAMPT circulating concentrations and gene expression levels in peripheral blood cells with lipid metabolism and fatty liver in human morbid obesity. Nutr Metab Cardiovasc Dis 2011; 21: 245-253.
6. Tan BK, Chen J, Digby JE, Keay SD, Kennedy CR, Randeva HS. Increased visfatin messenger ribonucleic acid and protein levels in adipose tissue and adipocytes in women with polycystic ovary syndrome: parallel increase in plasma visfatin. J Clin Endocrinol Metab 2006; 91: 5022-5028.
7. Zwirska-Korczala K, Sodowski K, Konturek SJ, et al. Postprandial response of ghrelin and PYY and indices of low-grade chronic inflammation in lean young women with polycystic ovary syndrome. J Physiol Pharmacol 2008; 59(Suppl 2): 161-178.
8. Herszenyi L, Lakatos G, Hritz I, Varga MZ, Cierny G, Tulassay Z. The role of inflammation and proteinases in tumor progression. Dig Dis 2012; 30: 249-254.
9. Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med 2010; 49: 1603-1616.
10. Korbut E, Ptak-Belowska A, Brzozowski T. Mechanisms promoting physiological cells progression into tumorigenesis. J Physiol Pharmacol 2012; 63: 565-570.
11. Berndt J, Kloting N, Kralisch S, et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005; 54: 2911-2916.
12. Tanaka M, Nozaki M, Fukuhara A, et al. Visfatin is released from 3T3-L1 adipocytes via a non-classical pathway. Biochem Biophys Res Commun 2007; 359: 194-201.
13. Garten A, Petzold S, Barnikol-Oettler A, et al. Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is constitutively released from human hepatocytes. Biochem Biophys Res Commun 2010; 391: 376-381.
14. Friebe D, Loffler D, Schonberg M, et al. Impact of metabolic regulators on the expression of the obesity associated genes FTO and NAMPT in human preadipocytes and adipocytes. PLoS ONE 2011; 6: e19526.
15. Laudes M, Oberhauser F, Schulte DM, et al. Visfatin/PBEF/NAMPT and resistin expressions in circulating blood monocytes are differentially related to obesity and type 2 diabetes in humans. Horm Metab Res 2010; 42: 268-273.
16. Dahl TB, Yndestad A, Skjelland M, et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation 2007; 115: 972-980.
17. Sommer G, Garten A, Petzold S, et al. Visfatin/PBEF/Nampt: structure, regulation and potential function of a novel adipokine. Clin Sci (Lond) 2008; 115: 13-23.
18. Moschen AR, Kaser A, Enrich B, et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007; 178: 1748-1758.
19. Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307: 426-430.
20. Imai S. Nicotinamide phosphoribosyltransferase (Nampt): A link between NAD biology, metabolism, and diseases. Curr Pharm Des 2009; 15: 20-28.
21. Shackelford RE, Bui MM, Coppola D, Hakam A. Over-expression of nicotinamide phosphoribosyl-transferase in ovarian cancers. Int J Clin Exp Pathol 2010; 3: 522-527.
22. Reddy PS, Umesh S, Thota B, et al. PBEF1/NAmPRTase/visfatin: a potential malignant astrocytoma/glioblastoma serum marker with prognostic value. Cancer Biol Ther 2008; 7: 663-668.
23. Patel ST, Mistry T, Brown JE, et al. A novel role for the adipokine visfatin/pre-B cell colony-enhancing factor 1 in prostate carcinogenesis. Peptides 2010; 31: 51-57.
24. Buldak RJ, Buldak L, Polaniak R, et al. Visfatin affects redox adaptative responses and proliferation in Me45 human malignant melanoma cells: an in vitro study. Oncol Rep 2013; 29: 771-778.
25. Kramer-Marek G, Serpa C, Szurko A, et al. Spectroscopic properties and photodynamic effects of new lipophilic porphyrin derivatives: efficacy, localisation and cell death pathways. J Photochem Photobiol B 2006; 84: 1-14.
26. LeBel CP, Ischiropoulos H, Bondy SC. Evaluation of the probe 2', 7'-dichlorofluorescin as an indicator of reactive oxygen species formation and oxidative stress. Chem Res Toxicol 1992; 5: 227-231.
27. Romacho T, Azcutia V, Vazquez-Bella M, et al. Extracellular PBEF/NAMPT/visfatin activates pro-inflammatory signalling in human vascular smooth muscle cells through nicotinamide phosphoribosyltransferase activity. Diabetologia 2009; 52: 2455-2463.
28. Lee WJ, Wu CS, Lin H, et al. Visfatin-induced expression of inflamatory mediators in human endothelial cells through the NF-β pathway. Int J Obes 2009; 33: 465-472.
29. Oita RC, Ferdinando D, Wilson S, Bunce C, Mazzatti DJ. Visfatin induces oxidative stress in differentiated C2C12 myotubes in an Akt-and MAPK-independent, NFkB-dependent manner. Pflugers Arch 2010; 459: 619-630.
30. Adya R, Tan BK, Punn A, Chen J, Randeva HS. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Cardiovasc Res 2008; 78: 356-365.
31. Li Y, Zhang Y, Dorweiler B, et al. Extracellular Nampt promotes macrophage survival via a nonenzymatic interleukin-6/STAT3 signaling mechanism. J Biol Chem 2008; 283: 34833-34843.
32. Lu Ch, Kerbel RS. Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J Cell Biol 1993; 120: 1281-1288.
33. Von Felbert V, Cordoba F, Weissenberger J, et al. Interleukin-6 gene ablation in a transgenic mouse model of malignant skin melanoma. Am J Pathol 2005; 166: 831-841.
34. Jones SA, Horiuchi S, Topley N, Yamamoto N, Fuller GM. The soluble interleukin 6 receptor: mechanisms of production andimplications in disease. FASEB J 2001; 15: 43-58.
35. Varney ML, Li A, Dave BJ, Bucana CD, Johansson SL, Singh RK. Expression of CXCR1 and CXCR2 receptors in malignant melanoma with different metastatic potential and their role in interleukin-8 (CXCL-8)-mediated modulation of metastatic phenotype. Clin Exp Metastasis 2003; 20: 723-731.
36. Enzmann V, Faude F, Kohen L, Wiedemann P. Secretion of cytokines by human choroidal melanoma cells and skin melanoma cell lines in vitro. Ophthalmic Res 1998; 30: 189-194.
37. Giorgini S, Trisciuoglio D, Gabellini C, et al. Modulation of bcl-xL in tumor cells regulates angiogenesis through CXCL8 expression. Mol Cancer Res 2007; 5: 761-771.
38. Gabellini C, Trisciuoglio D, Desideri M, et al. Functional activity of CXCL8 receptors, CXCR1 and CXCR2, on human malignant melanoma progression. Eur J Cancer 2009; 45: 2618-2627.
39. Lazar-Molnar E, Hegyesi H, Toth S, Falus A. Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine 2000; 12: 547-554.
40. Singh RK, Varney ML, Bucana CD, Johansson SL. Expression of interleukin-8 in primary and metastatic malignant melanoma of the skin. Melanoma Res 1999; 9: 383-387.
41. Gebhardt C, Averbeck M, Viertel A, et al. Ultraviolet-B irradiation enhances melanoma cell motility via induction of autocrine interleukin 8 secretion. Exp Dermatol 2007; 16: 636-643.
42. Li Q, Verma IM. NF-β regulation in the immune system. Nat Rev Immunol 2002; 2: 725-734.
43. Bryk D, Zapolska-Downar D, Malecki M, Hajdukiewicz K, Sitkiewicz D. Trans fatty acids induce a proinflammatory response in endothelial cells through ROS-dependent nuclear factor-B activation. J Physiol Pharmacol 2011; 62: 229-238.
44. Amaravadi R, Thompson CB. The survival kinases Akt and Pim as potential pharmacological targets. J Clin Invest 2005; 115: 2618-2624.
45. Knapp M. Cardioprotective role of sphingosine-1-phosphate. J Physiol Pharmacol 2011; 62: 601-607.
46. Jia SH, Li Y, Parodo J, et al. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest 2004; 113: 1318-1327.
47. Ognjanovic S, Ku TL, Bryant-Greenwood GD. Pre-B-cell colony enhancing factor is a secreted cytokine-like protein from the human amniotic epithelium. Am J Obstet Gynecol 2005; 193: 273-282.
48. Baldea I, Filip AG. Photodynamic therapy in melanoma-an update. J Physiol Pharmacol 2012; 63: 109-118.
49. Reeder CB, Ansell SM. Novel therapeutic agents for B-cell lymphoma: developing rational combinations. Blood 2011; 117: 1453-1462.
50. Wang P, Xu TY, Guan YF, Su DF, Fan GR, Miao CY. Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: role of nicotinamide mononucleotide. Cardiovasc Res 2008; 81: 370-380.
51. Xie H, Tang SY, Luo XH, et al. Insulin-like effects of visfatin on human osteoblasts. Calcif Tissue Int 2007; 80: 201-210.